MedTrace Logo

Peak Bronchoprotection Conferred by Levosalbutamol and Racemic Salbutamol

NCT00830882 · Status: WITHDRAWN · Phase: PHASE4 · Type: INTERVENTIONAL

Last updated 2012-06-12

No results posted yet for this study

Summary

The objective of this study is to compare the peak dose relative bronchoprotection offered by levosalbutamol and racemic salbutamol in mild to moderate asthmatics preselected into two groups on the basis of their beta-2 adrenoreceptor polymorphisms.

Conditions

Interventions

DRUG

levosalbutamol

2 puffs four times a day for 2 weeks

DRUG

racemic salbutamol

2 puffs four times a day for 2 weeks

DRUG

placebo

2 puffs four times a day for 2 weeks

Sponsors & Collaborators

  • University of Dundee

    lead OTHER

Principal Investigators

  • Karine L Clearie, MBBS, MRCP · Asthma and Allergy Research Group

  • Brian J Lipworth, MBchB · Asthma and Allergy Research Group

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-01-31
Primary Completion
2010-01-31
Completion
2010-01-31

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00830882 on ClinicalTrials.gov